LeMaitre Vascular, Inc.
LeMaitre Vascular, Inc. is a global provider of medical devices and human tissue cryopreservation services primarily used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices targeting vascular surgeons… From the company’s description.
Margins and return on equity change in ; everything else in percent. Fewer shares and less debt are shown plainly, not as bad news — it depends what you make of buybacks. Dotted labels explain each measure. is shown separately from the annual figures.
What LeMaitre Vascular, Inc. does
In the company’s own words
LeMaitre Vascular, Inc. is a global provider of medical devices and human tissue cryopreservation services primarily used in the treatment of peripheral vascular disease, end-stage renal disease, and cardiovascular disease. The company develops, manufactures, and markets vascular devices targeting vascular surgeons and adjacent specialties including cardiac surgeons, general surgeons, and neurosurgeons. Founded in 1983 by vascular surgeon George D. LeMaitre, the company has grown through 25 complementary acquisitions combined with internal research and development.
LeMaitre's diversified portfolio comprises six product categories with twenty-four distinct product types, including biologic patches, vascular grafts, embolectomy catheters, carotid shunts, closure systems, and valve cutters. The company's biologic offerings, representing 53 percent of sales, include XenoSure patches, CardioCel and VascuCel patches, Artegraft bovine carotid arteries, Omniflow II biosynthetic grafts, and RestoreFlow allograft cryopreservation services. No single product type exceeds 20 percent of revenues. The company estimates the worldwide market for peripheral vascular devices exceeds nine billion dollars, with its addressable market approximately one billion dollars.
The company operates through a direct sales force comprising 160 sales representatives and export managers across North America, Europe, and Asia Pacific, generating approximately 95 percent of net sales through direct-to-hospital channels. Headquarters are located in Burlington, Massachusetts, with primary manufacturing facilities there, plus specialized operations in North Brunswick, New Jersey for Artegraft production and Fox River Grove, Illinois for RestoreFlow allograft processing. Additional regional offices span Europe and Asia Pacific.
LeMaitre competes in niche segments under 400 million dollars in annual worldwide revenue, emphasizing differentiated features, consistent quality, and availability. The company's strategy focuses on direct sales force expansion, acquisition of complementary products, and obtaining regulatory approvals in new geographies. The company maintains ISO 13485 certification at its medical device manufacturing facilities and AATB accreditation for tissue processing operations. Visit www.lemaitre.com for additional information.
Company details
- Sector
- Health Care
- Industry (SIC)
- Surgical & Medical Instruments
- Headquarters
- BURLINGTON, MA
- Fiscal year end
- December
- CIK
- 1158895
- SIC
- 3841
Financial performance, year by year
Fiscal 2013–2025 · USDThe full income statement, balance sheet and cash flow for each of these years — every figure traceable to its filing — is on the Financials tab with a free account.
Who owns LeMaitre Vascular, Inc. — and what changed
Funds as of 2026Q2 · superinvestors as of 2026-06-30
Largest fund holders · LeMaitre Vascular, Inc.’s weight in each
Fund ownership is a floor, not a census — pensions, insurers and people holding shares directly are not visible here.
LeMaitre Vascular, Inc.’s bonds, as funds hold them
Funds report holding 1 issues of LeMaitre Vascular, Inc.’s debt, $25.08M at market value — what funds hold, not the company’s total debt. Weighted-average coupon 2.50%, maturing 2030 to 2030.
Fund ownership counts N-PORT filers only, so it is a floor rather than a census — pensions, insurers and direct holders are not visible here, and the remainder is not “held by individuals”.
Every fund and institutional holder, quarter by quarter, is on the Ownership tab with a free account.
Recent filings
All filings →Each filing opens into its own statements and disclosures here.
Put this business in context.
Compare this company with peers, find it in your funds and follow its financial history with your connected AI:
- “How do LeMaitre Vascular, Inc. and its peers compare on margins and cash generation over ten years?”
- “Where did five years of LeMaitre Vascular, Inc.'s earnings go — cash, debt, buybacks, reinvestment?”
- “What changed in LeMaitre Vascular, Inc.'s last four quarterly filings that the numbers alone won't show?”